Safety and tolerability of mirvetuximab soravtansine monotherapy for folate receptor alpha-expressing recurrent ovarian cancer: An integrated safety summary

By sjmartinez • December 13, 2024

Moore KN, Lorusso D, Oaknin A, Oza A, Colombo N, Van Gorp T, O'Malley DM, Banerjee S, Murphy CG, Harter P, Konecny GE, Pautier P, Method M, Wang Y, Coleman RL, Birrer M, Matulonis UA. Safety and tolerability of mirvetuximab soravtansine monotherapy for folate receptor alpha-expressing recurrent ovarian cancer: An integrated safety summary. Gynecol Oncol. 2024 Dec;191:249-258. doi: 10.1016/j.ygyno.2024.10.013. Epub 2024 Oct 25. PMID: 39461270.

Tags: ADC, antibody-drug conjugate, Folate receptor alpha, Hematology/Oncology, Integrated safety, Mirvetuximab soravtansine, Ocular adverse events, ovarian cancer, Publications

An IL-12 renaissance: Engineering tumor-restricted IL-12 to improve solid tumor T cell therapies

Ishihara J, Lee JK, Priceman SJ. An IL-12 renaissance: Engineering tumor-restricted IL-12 to improve solid tumor T cell therapies. Mol Ther. 2025 Dec 23:S1525-0016(25)01041-X. doi:[...]

CRESTONE: A Phase II Study of the Efficacy and Safety of the HER3 Monoclonal Antibody, Seribantumab, in Solid Tumors With Neuregulin-1 (NRG1) Fusions

Patil T, Lin JJ, Cheema PK, Carrizosa DR, Burkard ME, Elamin YY, Desai J, Patel JD, Nagasaka M, Reckamp KL, Waqar SN, Bauman JR, Schram[...]

Clinical Feasibility of Circulating Tumor DNA in Patients with Advanced Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab

Hwang S, Shin DJ, Kang B, Kang H, Lee SH, Kim JS, Joung JG, Jain S, Olsen S, Becker L, Finn RS, Llovet JM, Kim[...]